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http://dx.doi.org/10.1016/j.jfma.201This Phase-IV study evaluated the human rotavirus (RV) vaccine Rotarix (RIX4414) to provide
additional local clinical data to the Taiwan Food and Drug Association (NCT01198769). Healthy
infants aged 6e12 weeks who were given a hepatitis B immunoglobulin (HBIg) dose after birth,
received two doses of RIX4414 (0, 2-month schedule). Anti-RV IgA antibody concentrations
were measured using ELISA. A total of 15 infants were enrolled, and included in the
according-to-protocol cohort. The anti-RV IgA antibody seroconversion rate 2 months post-
Dose 2 was 100% (95% confidence intervalZ 78.2e100) and the geometric mean concentration
was 254.7 U/ml (95% confidence interval Z 145.0e447.7). Two episodes of gastroenteritis
were reported, and one stool sample was tested for RV, which was negative. No fatal serious
adverse events were reported during the study period between November 2010 and April 2011.
The two-dose regimen of RIX4414 was highly immunogenic and safe when administered to
healthy Taiwanese infants who received a HBIg dose after birth.
Trial registration number: NCT01198769.
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Worldwide, rotavirus (RV) is a major cause of severe
dehydrating diarrhea in children aged <5 years.1 Globally,
RV-related diarrhea results in approximately 453,000& Formosan Medical Association. All rights reserved.
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5% of all deaths in children aged <5 years, each year.2 RV
diarrhea is widely prevalent throughout the Asia-Pacific
region.3,4 In Taiwan, RV is the leading cause of infectious
gastroenteritis (GE), estimated to affect one child in every
two to five children aged <5 years who will require medical
care.5 According to an epidemiology study conducted in
2007, 55.78% of children in Taiwan experienced acute
diarrhea ranging from 15.5% among infants aged <6 months
to 82.2% among children aged 4e5 years.6
Owing to the hyperendemicity and high hepatitis B
surface antigen (HBsAg) carrier rate (15e20%) for pregnant
women in Taiwan, it was strategically decided to admin-
ister a dose of hepatitis B immunoglobulin (HBIg) after birth
to infants born to hepatitis B envelope antigen (HBeAg)-
positive mothers.7 This strategy was implemented in addi-
tion to the national hepatitis B (HB) vaccination program
launched in 1984.8 It has been observed that a combination
of HBIg and HB vaccination significantly decreased the risk
of perinatal transmission of hepatitis B virus (HBV).9 The
efficacy of protecting infants from hepatitis B virus infec-
tion due to the use of HBIg is >90%10 and the HB vaccination
coverage rate is >96%.11
An oral, live, attenuated human RV vaccine, Rotarix
(RIX4414; GlaxoSmithKline, Belgium) is widely available.12
It has been found to be immunogenic, efficacious, and
safe, including when coadministered with other routine
childhood vaccines, in studies conducted across the USA,
Europe, Latin America, Asia, and Africa.13e18
Given that there is a theoretical concern with respect to
the effect of immunoglobulin preparations on the response
elicited by vaccines and upon the request of the Food and
Drug Administration of Taiwan, the present postlicensure
study was conducted to generate local clinical data on the
immunogenicity and safety of RIX4414 when administered
in healthy Taiwanese infants who had received a dose of
HBIg after birth, to assess the potential impact of HBIg on
the immune response to RIX4414.Table 1 Definitions of Grade 3 solicited general
symptoms.
Symptoms Grade 3 intensity definition
Irritability/
Fussiness
Crying that could not be comforted/
prevented normal daily activities
Diarrhea 6 looser than normal stools/d
Vomiting 3 episodes of vomiting/d
Fever Rectal temperature >39.5C
Loss of appetite No food intake
Cough/Runny nose Prevented normal daily activitiesMaterials and methods
This Phase IV, open-labeled, single-center, single-group
study (NCT01198769) was conducted at the National
Taiwan University Hospital, Taipei, Taiwan between
November 2010 and April 2011. Healthy infants aged 6e12
weeks, who had received a dose of HBIg after birth,
received two oral doses of RIX4414 (0, 2-month schedule).
RIX4414 was coadministered with other routine childhood
vaccinations as recommended by the local immunization
schedule.
Infants were excluded from participating in the study if
they received any immunosuppressants/immunoglobulins
(except for HBIg after birth), or investigational/non-
registered or unforeseen vaccine/drug other than the study
vaccine, or if they were previously vaccinated against RV, if
they had confirmed cases of RV GE previously, or if they
experienced GE 7 days before Dose 1 of the study vaccine.
Other reasons for exclusion included infants’ concurrent
participation in another study, allergic reaction to any
vaccine component, or serious chronic illness.The national Independent Ethics Committee reviewed
and approved all study-related documents. The guidelines
of Good Clinical Practice and the Declaration of Helsinki
were abided by during the conduct of the study. Parents/
guardians provided written informed consent before any
study-related procedures were performed.
The lyophilized formulation of RIX4414 was developed
and manufactured by GlaxoSmithKline, Belgium. Each dose
(1 mL) of RIX4414 contained at least 106.0 median cell
culture infective dose of the active virus strain.
Blood samples were collected prevaccination and 2
months post-Dose 2 of RIX4414 to determine the anti-RV IgA
antibody concentrations using an in-house enzyme linked
immunosorbent assay (assay cut-off Z 20 U/mL).
Following each dose of RIX4414, the percentage of
infants reporting solicited general (fever, fussiness/irrita-
bility, loss of appetite, cough/runny nose, diarrhea, and
vomiting) and unsolicited symptoms during the 8-day and
31-day postvaccination follow-up periods, respectively,
were recorded. Intensity of solicited general symptoms was
assessed on a 0e3 scale with grade 3 symptoms considered
as severe (Table 1). Serious adverse events were recorded
from Dose 1 of the vaccine until the end of the study
period.
Stool samples were collected for any GE episodes from
Dose 1 of RIX4414 until 2 months post-Dose 2, and tested for
the presence of RV using enzyme linked immunosorbent
assay.
A sample size of 15 infants was predefined assuming an
overall seroconversion rate of 90%.
Seroconversion rates (defined as the appearance of anti-
RV IgA antibody concentration 20 U/mL in infants who
were seronegative before Dose 1 of RIX4414) and geometric
mean concentration (GMC) were calculated with 95%
confidence interval (CI). The GMCs were calculated by
taking the antilog of the mean of the log concentrations
transformations.
The percentage of infants reporting all the symptoms
were calculated with their exact 95% CIs.
All statistical analyses were performed using SAS 9.1
(SAS, Cary, NC, USA) and Proc StatXact-7 (Cytel Inc.,
Cambridge, MA, USA).Results
A total of 15 infants were enrolled in the study. There were
no withdrawals. None of the infants were eliminated from
576 C.-Y. Lu et al.the study. Therefore, the total vaccinated cohort and the
according-to-protocol cohort were the same. The median
age of infants was 9 weeks (range, 8e10 weeks) at the time
of Dose 1 of RIX4414 and 18 weeks (range, 15e20 weeks) at
Dose 2; 53.3% of infants were female and the majority of
infants (93.3%) were of east Asian heritage.
Two months post-Dose 2 of RIX4414, 100% (95% CI
Z 78.2e100) of infants had anti-RV IgA antibody concen-
trations 20 U/mL. The overall GMC was 254.7 U/ml (95%
CI Z 145.0e447.7).
The overall incidence of symptoms (solicited and unso-
licited) recorded during the 8-day follow-up period was
86.7% (95% CI Z 59.5e98.3). Between both doses of
RIX4414, there was no increase in incidence of solicited or
unsolicited symptoms. During the 8-day follow-up period,
irritability was the most frequently reported solicited
general symptom (73.3%; 95% CI Z 44.9e92.2) followed by
loss of appetite (66.7%; 95% CI Z 38.4e88.2]) (Fig. 1).
During this period, the most common Grade 3 solicited
general symptom was irritability (13.3%; 95% CIZ 1.7e40.5)
followed by vomiting (6.7%; 95% CI Z 0.2e31.9) (Fig. 1).
During the 31-day follow-up period, at least one unsolicited
symptom was reported for 26.7% (95% CIZ 7.8e55.1) of the
infants. Eczema was the most frequently reported unsolic-
ited general symptom (13.3%; 95% CIZ 1.7e40.5) during the
31-day follow-up period. Grade 3 unsolicited general
symptoms were not reported. One serious adverse event,
bronchiolitis, was recorded 17 days post-Dose 2 of RIX4414
in one infant. It lasted for 25 days; however, it was consid-
ered unrelated to the vaccine by the investigator. No fatal
cases were reported during the study period.
Throughout the study period, two GE episodes were re-
ported in two infants. A GE stool sample was collected from
only one infant, in which there was no RV identified.
Discussion
This postlicensure study evaluated the immunogenicity and
safety of RIX4414 in Taiwanese infants born to HBeAg-Figure 1 Percentage of infants reporting each solicited
general symptom during the 8-day follow-up period post-
vaccination. Error bars represent 95% confidence interval.positive mothers who had received a dose of HBIg after
birth. The results of this study indicate that the use of HBIg
did not negatively impact the immunogenicity and safety
profile of two doses of RIX4414.
The immunogenicity results of this study are consistent
with an earlier Phase III Asian clinical trial. The results of
this previous study reported a seroconversion rate of 85.7%
(95% CI Z 69.7e95.2) and corresponding GMC of 105.8
(95% CI Z 67.4e166.2) 1e2 months post-Dose 2 in healthy
Taiwanese infants who did not receive HBIg after birth.16
Although the previous study was a large trial, the immu-
nogenicity cohort of Taiwanese infants was low (RIX4414
group Z 35 infants).16 Our results suggest that immunoge-
nicity of RIX4414 was not compromised despite the use of
HBIg.
The safety results of this study indicate that RIX4414 is
well tolerated in vaccinated infants. No increase in the
incidence of solicited or unsolicited symptoms between two
doses of RIX4414 suggests safety of the two-dose regimen.
While a recent Korean study reported irritability as the most
common solicited general symptom, cough/runny nose was
reported to be the second most common solicited general
symptom, which is not the case in our study. Similarly,
among unsolicited symptoms, the previously conducted
study reported nasopharyngitis as themost common,19 while
the current study found eczema to be the most prevalent.
It has been suggested that immunoglobulins might
interfere with immune responses to live virus vaccina-
tions.20 However, the present study suggested that HBIg
does not alter the immune response elicited by RIX4414.
Additionally, the United States Advisory Committee on
Immunization Practices confirms the administration of RV
vaccines before/concurrently/after administration of any
immunoglobulin.20
The results of this study should be interpreted with
caution given that the sample size was modest and the
enrollment was from a single center. The success of the HBV
immunization program and provision of HBIg in Taiwan has
led to a decline in the HBsAg carrier population resulting in
the limited sample size. In addition, Rotarix is commercially
available in Taiwan. Therefore, enrolling a larger group of
infants without previous exposure to RV vaccination was
a challenge. Despite these limitations, the results from this
study are similar to the results observed in a previous study
conducted in Taiwan with the same vaccine.16
In conclusion, the data from this study support the
administration of RV vaccination in infants who have been
given HBIg within 24 hours after birth, as immunogenicity of
Rotarix was not compromised despite the use of HBIg.
Trademarks
Rotarix is a registered trademark of GlaxoSmithKline group
of companies.
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